Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives

(2019) Claudio Vernieri et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

AMPK directly activates mTORC2 to promote cell survival during acute energetic stress

(2019) Dubek Kazyken et al.   Science Signaling

Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations

(2019) Indrė Januškevičienė et al.   LIFE SCIENCES

Tumor suppressor miR-128-3p inhibits metastasis and epithelial–mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer

(2018) Lili Zhao et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Treatment of advanced HER2-positive breast cancer: 2018 and beyond

(2018) Noam Pondé et al.   CANCER TREATMENT REVIEWS

Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects

(2018) Mariana Brandão et al.   Expert Review of Anticancer Therapy

Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

(2018) Lucy Ireland et al.   ONCOGENE

Entinostat for the treatment of breast cancer

(2017) Dario Trapani et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition

(2017) Mei Hua Jin et al.   MOLECULAR CANCER THERAPEUTICS

A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance

(2017) Ji-Hak Jeong et al.   MOLECULAR CELL

MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models

(2016) Kaifeng Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling

(2016) Ming Ding et al.   NATURE CELL BIOLOGY

Entinostat (SNDX-275) for the treatment of non-small cell lung cancer

(2015) Rossana Ruiz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells

(2015) Hui Lyu et al.   Oncotarget

Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes In Vitro and in Male C57BL/6 Mice

(2014) Matei Mireuta et al.   ENDOCRINOLOGY

Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment

(2013) H. Reuveni et al.   CANCER RESEARCH

Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin

(2013) K. Friedbichler et al.   MOLECULAR CANCER THERAPEUTICS

Current approaches and future directions in the treatment of HER2-positive breast cancer

(2012) Sara A. Hurvitz et al.   CANCER TREATMENT REVIEWS

A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma

(2012) Y Yang et al.   ONCOGENE

Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN–AKT pathway

(2012) T Palumbo et al.   ONCOGENE

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance

(2011) Xiaoping Huang et al.   CANCER LETTERS

Reduced miR-128 in Breast Tumor-Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5

(2011) Y. Zhu et al.   CLINICAL CANCER RESEARCH

Entinostat for treatment of solid tumors and hematologic malignancies

(2011) Jeffrey Knipstein et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

MicroRNA-30a Sensitizes Tumor Cells to cis-Platinum via Suppressing Beclin 1-mediated Autophagy

(2011) Zhenyou Zou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Trastuzumab resistance: all roads lead to SRC

(2011) Senthil K Muthuswamy   NATURE MEDICINE

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

(2010) X. Huang et al.   CANCER RESEARCH

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression

(2009) X. Huang et al.   CANCER RESEARCH

Serine/Threonine Phosphatases: Mechanism through Structure

(2009) Yigong Shi   CELL

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

(2008) E. Buck et al.   CANCER RESEARCH

Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake

(2008) Y. Shang et al.   MOLECULAR CANCER THERAPEUTICS